TCR CAR T-cells have successfully targeted intracellular synovial sarcoma X breakpoint 2 (SSX2) in the context of HLA*0201 as well as mutated nucleophosmin (NPM1) in the context of HLA-A2 in AML cancer cell lines [55,56]. Here, SSX2 is linked to acute myeloid leukemia.